China Reports 7,000 Chikungunya Cases; Know Symptoms, Cause And Treatment
In a public notice issued on Sunday (Aug 3), the retail pharmacies have been ordered to start real-name registration and to keep records when selling medications to treat symptoms of chikungunya, including fever, rashes and joint pain.
People who have travelled from chikungunya-affected cities in Guangdong have been told to self-monitor for symptoms, according to a report in South China Morning Post.
Some hotels and restaurants that failed to promptly eliminate mosquito breeding sites have already been penalised by the authorities. At least 12 other cities apart from Foshan have also reported infections, with nearly 3,000 cases reported last week alone.
Meanwhile, Hong Kong reported its first imported chikungunya fever case in six years on Saturday last week, raising the risk of local transmissions in the city. Authorities have been told to step up efforts to fight a potential outbreak. Data has shown that "breeding of the pest that can transmit chikungunya fever is 'fairly extensive' in 70 per cent of the city's surveyed areas".
What is chikungunya?
Chikungunya is a viral disease transmitted to humans primarily through the bite of infected mosquitoes, mainly Aedes aegypti and Aedes albopictus. Humid weather during the rainy season creates ideal conditions for mosquito breeding.
Despite being uncommon in China, Chikungunya epidemics are frequent in South and Southeast Asia as well as some regions of Africa.
Symptoms of chikungunya:
One of the major symptoms of chikungunya is intense joint pain and stiffness, affecting the hands, wrists, ankles and knees. This kind of joint discomfort is much more severe compared to typical viral infections and is a key distinguishing sign.
Apart from joint pain, muscle pain, fatigue and overall weakness are also common in chikungunya. Many chikungunya patients develop a red, patchy rash on the torso, limbs, or face. Most people develop these symptoms within three to seven days of getting bitten.
Chikungunya treatment
There is no specific chikungunya treatment, but doctors focus on managing symptoms. Treatment for symptoms can include rest, fluids, and the use of analgesics and antipyretics. Nonsteroidal anti-inflammatory drugs can be used to help with acute fever and pain.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
4 minutes ago
- Time of India
Mosquito bites turn deadly after chikungunya virus cases cross 240,000, CDC issues urgent travel warning over spread from China to the world
U.S. health officials have issued a stark warning for travellers heading to China, after a surge in chikungunya virus cases hit Guangdong province. The CDC released a travel advisory on August 1 urging Americans to exercise enhanced precautions, marking the region a hotspot amid a global wave of infections. CDC sounds the alarm as China battles chikungunya surge Foshan, a major city in Guangdong, has recorded over 7,000 confirmed cases since June. Chinese authorities held an emergency conference last month to strategise prevention efforts and promised to release early warnings through all available platforms to curb the spread. Global cases cross 240,000, where else is it spreading? The 2025 chikungunya outbreak is not limited to China. According to the European Centre for Disease Prevention and Control, over 240,000 people across the globe have been infected, with 90 fatalities reported so far. Other nations battling active outbreaks include Bolivia, Kenya, Madagascar, Mauritius, Mayotte, Réunion, Somalia and Sri Lanka. 🚨Chikungunya Outbreak in China's Guangdong Province: Over 7,000 cases of the Chikungunya virus, transmitted by daytime-active Aedes mosquitoes, have been reported. Foshan City is the most affected, prompting urgent government measures. Symptoms include fever, joint pain, muscle… Additionally, countries like Brazil, Colombia, Mexico, India, Pakistan, Philippines, Thailand and Nigeria are now being flagged as high-risk zones, even though official outbreaks have not yet been declared. What exactly is chikungunya? First identified in Tanzania in 1952, chikungunya is a mosquito-borne virus transmitted by Aedes mosquitoes. The disease shares several symptoms with dengue and Zika but can escalate more severely in vulnerable individuals. The World Health Organization estimates 5.6 billion people globally are at risk of contracting arboviral infections such as chikungunya, dengue and yellow fever. Symptoms that should not be ignored Health experts describe chikungunya symptoms as sudden and intense. The CDC outlines high fever, joint pain and swelling, muscle aches, headaches and skin rashes as the most common signs. Although most infections resolve within two to 12 days, some patients, particularly the elderly, newborns, and those with pre-existing health issues—may experience life-threatening complications including cardiovascular or neurological distress. Is there a cure or vaccine? Currently, there are no antiviral treatments available. Doctors usually prescribe medications to manage fever and joint pain. Two vaccines have been approved but are not yet widely accessible. A U.S. vaccine was paused in May due to adverse event reports. With no definitive cure and a rising death toll, prevention remains the most powerful defence.
&w=3840&q=100)
First Post
an hour ago
- First Post
Kennedy Jr says US health dept will halt $500 mn funding for mRNA vaccine projects
The US Health Department will cancel $500 million worth of mRNA vaccine projects targeting COVID-19, the flu, and other respiratory viruses, Health Secretary Robert F Kennedy Jr. announced on Tuesday. The decision affects 22 projects. read more US President Donald Trump holds an executive order on prescription drug pricing next to US Health and Human Services (HHS) Secretary Robert F Kennedy, Jr, during a press conference in the Roosevelt Room at the White House. Reuters The Department of Health and Human Services (HHS) will cancel funding and contracts for several vaccine projects aimed at fighting respiratory viruses like COVID-19 and the flu. Health Secretary Robert F. Kennedy Jr. on Tuesday announced that 22 vaccine projects using mRNA technology, worth a total of $500 million, will be shut down. The move reflects Kennedy's long-standing skepticism about vaccines, particularly those using mRNA technology. Since taking office, Kennedy has reversed previous recommendations on COVID-19 vaccines, dismissed the expert panel responsible for vaccine advice, and refrained from strongly endorsing immunisation even as measles cases rise. STORY CONTINUES BELOW THIS AD In a video posted on social media, Kennedy criticised mRNA vaccines and explained that the decision would impact major pharmaceutical companies, including Pfizer and Moderna, which are developing mRNA-based vaccines for COVID-19, the flu, and bird flu (H5N1). 'To replace the troubled mRNA programs, we're prioritising the development of safer, broader vaccine strategies, like whole-virus vaccines and new platforms that don't fail when viruses mutate,' Kennedy said. However, public health experts strongly disagree with the move. Mike Osterholm, a leading infectious disease specialist from the University of Minnesota, called it 'the most dangerous decision in public health' he's seen in 50 years. He stressed that mRNA technology allows for faster vaccine development, which is crucial in responding to new pandemics. Dr. Paul Offit, a vaccine expert at Children's Hospital of Philadelphia, said the decision is especially risky with the threat of bird flu still looming. 'mRNA vaccines have certainly saved millions of lives,' he said. Beyond infectious diseases, researchers are exploring mRNA technology for other uses, including cancer treatments. Earlier this year, tech billionaire Larry Ellison praised its potential for cancer therapy at a White House event. Unlike traditional vaccines that rely on growing viruses in eggs or cell cultures, mRNA vaccines use a snippet of genetic code to instruct the body to make a harmless piece of a virus, enough to trigger immune protection. STORY CONTINUES BELOW THIS AD In its statement, HHS clarified that this decision applies only to the 22 cancelled projects and does not affect other uses of mRNA technology within the department. While mRNA vaccines are already approved for COVID-19 and RSV, no flu vaccine using the technology has yet been authorised. Moderna, which is developing a combined COVID-flu mRNA shot, had said mRNA could speed up flu vaccine production compared to traditional methods.
Indian Express
2 hours ago
- Indian Express
US Health Secretary RFK Jr. cancels $500 million in funding for vaccine development
The US Department of Health and Human Services has decided to cancel contracts and cease funding of mRNA vaccine development activities that were being developed to fight respiratory viruses like flu and COVID-19. The biomedical research unit affected by the decision is Biomedical Advanced Research and Development Authority which helps companies to develop medical supplies to address health threats in the public, and it had provided billions of dollars for the development of vaccines during the COVID-19 pandemic. US Health Secretary Robert F. Kennedy Jr., who has been a vaccine critic himself for a long time, announced in a statement on Tuesday that $500 million worth of vaccine development projects, all under the mRNA technology, will be paused. We reviewed the science, listened to the experts, and acted. BARDA is terminating 22 mRNA vaccine development investments because the data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu. We're shifting that funding toward… — Secretary Kennedy (@SecKennedy) August 5, 2025 With this decision, a total of 22 projects are set to be affected out of which some of those were being led by America's leading pharmaceutical companies like Pfizer and Moderna to prevent flu, H5N1 and COVID-19 among others. The mRNA vaccines hold the credit for slowing down the coronavirus pandemic in 2020. In the statement, Kennedy said he wants the health department to move away from the mRNA vaccines and called on the department to start 'investing in better solutions.' 'We're shifting that funding toward safer, broader vaccine platforms that remain effective even as viruses mutate,' Kennedy said. Kennedy refrained from providing details on what those technologies might be as he asked the health department to move away from the development of mRNA vaccines. The health department added that it was also cancelling multiple pre-award solicitations, including proposals from Pfizer, Sanofi Pasteur, CSL Seqirus, Gritstone and others.
